餐后高血糖和心血管危險(xiǎn)因素(編輯修改稿)
2025-06-22 22:09 本頁面
【文章內(nèi)容簡介】 agata Cohort Population * * * * * C a r di o vascula r di s e a s e0. 90 00. 92 00. 94 00. 96 00. 98 01. 00 00 1 2 3 4 5 6 7Y ea r s* * * * * Tominaga M et al. Diabetes Care, 1999 NGT IFG DM All causes of death 0 1 2 3 4 5 6 7 Years The Funagata Cohort Population A ll c a us e s o f de a t h0. 88 00. 90 00. 92 00. 94 00. 96 00. 98 01. 00 00 1 2 3 4 5 6 7Y ea r s* * * * * C a r di o vascula r di s e a s e0. 94 00. 95 00. 96 00. 97 00. 98 00. 99 01. 00 00 1 2 3 4 5 6 7Y ea r s* * * * * Tominaga M et al. Diabetes Care, 1999 * * * * * NGT IGT DM Summary 1. Type 2 DM begins as a postprandial disease 2. Postprandial hyperglycemia contributes to elevations in HbA1c and plications 3. Treatment of postprandial hyperglycemia is critical to achieving optimal outes in type 2 DM 4. Nevertheless, treatment of postprandial hyperglycemia is inadequately addressed STOPNIDDM Study to Prevent Noninsulin Dependent Diabetes Mellitus STOP NIDDM Study design STOP NIDDM Placebo . (n=715) Acarbose 100mg . (n=714) –1 0 36 6 12 18 24 30 Months 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Visits Placebo n=1,429 3 months placebo 60 Closeout visit .: three times daily Chiasson JL, et al. Lancet 2022。359:2072–7. Acarbose reduces the risk of developing diabetes STOP NIDDM Acarbose reduces the incidence of type 2 diabetes in individuals with IGT Based on one positive OGTT 25% p= Based on two consecutive positive OGTTs 36% p= IGT: impaired glucose tolerance, OGTT: oral glucose tolerance test Chiasson JL, et al. Diabetologia 2022。45(Suppl. 2):A104. Acarbose has a rapid and sustained effect on diabetes risk ? Acarboseassociated reduction in risk of diabetes was evident after 1 year ? Acarbose significantly reduced the risk of diabetes at each followup time point ? The beneficial effe
環(huán)評公示相關(guān)推薦
鄂ICP備17016276號(hào)-1